

SECOND EDITION

INFECTIOUS DISEASE MANAGEMENT IN ANIMAL SHELTERS

EDITED BY

LILA MILLER

STEPHANIE JANECKO

KATE F. HURLEY



WILEY Blackwell

Table of Contents

[Cover](#)

[Title Page](#)

[Copyright Page](#)

[Dedication Page](#)

[Contributors](#)

[Preface](#)

[Acknowledgments](#)

[1 Introduction to Infectious Disease Management in Animal Shelters](#)

[1.1 Why This Book?](#)

[1.2 The Growth of Shelter Medicine](#)

[1.3 Capacity for Care: Blending Shelter Medicine and Management](#)

[1.4 Conclusion](#)

[References](#)

[2 Wellness](#)

[2.1 Introduction: Wellness Defined](#)

[2.2 The Critical Importance of Wellness Protocols for Shelters](#)

[2.3 The Problem-Oriented Approach to Shelter Medicine](#)

[2.4 Policy and Protocol Development](#)

[2.5 Wellness: Physical Health](#)

[2.6 Wellness: Behavioral Health](#)

[2.7 Proper Housing](#)

[2.8 Enrichment](#)

[2.9 Environmental Wellness](#)

[2.10 Conclusion](#)

[References](#)

[3 Data Surveillance](#)

[3.1 Introduction](#)

[3.2 Disease Surveillance](#)

[3.3 Length of Stay \(LOS\) in Shelters](#)

[3.4 Capacity for Care](#)

[3.5 Other Disease-Related Metrics](#)

[3.6 Software Needs](#)

[3.7 Shelters Without Shelter-Specific Software](#)

[3.8 The Future](#)

[3.9 Summary](#)

[References](#)

[4 Diagnostic Testing](#)

[4.1 Introduction](#)

[4.2 Obtaining Diagnostic Samples](#)

[4.3 Types of Diagnostic Tests](#)

[4.4 Indications for Diagnostic Testing](#)

[4.5 Accuracy and Testing Strategy](#)

[4.6 Standard Operating Procedures](#)

[4.7 Conclusion](#)

[References](#)

[5 Necropsy Techniques](#)

[5.1 Introduction](#)

[5.2 Why Sample Tissues at Necropsy?](#)

[5.3 The Necropsy](#)

[5.4 Steps in Performing a Necropsy](#)

[5.5 The Diagnostic Shelter Necropsy](#)

[5.6 Other Shelter Necropsies](#)

[5.7 Conclusion](#)

[References](#)

[6 Outbreak Management](#)

[6.1 Introduction](#)

[6.2 Infectious Disease Outbreaks](#)

[6.3 Infectious Disease and Outbreak Response Plan](#)

[6.4 Outbreak Prevention](#)

[6.5 Outbreak Detection](#)

[6.6 Outbreak Investigation](#)

[6.7 Outbreak Epidemiology](#)

[6.8 Control Measures](#)

[6.9 Decision-Making](#)

[6.10 Working with the Media](#)

[6.11 Community Considerations](#)

[6.12 Conclusion](#)

[6.A Sample Disease Outbreak Tracking Form](#)

[References](#)

[7 Pharmacology](#)

[7.1 Principles of Drug Decision Making and Therapeutics](#)

[7.2 Searching for and Applying Evidence for Efficacy: Is the Drug Likely to Improve Animal Outcomes?](#)

[7.3 Drug Options Should be Refined Based on Efficacy by Consideration of Constraints on those Options](#)

[7.4 Application of Decision Making to Antibiotics](#)

[7.5 The Shelter Pharmacy](#)

[7.6 Conclusion](#)

[References](#)

[8 Sanitation](#)

[8.1 Introduction](#)

[8.2 Components of the Sanitation Process](#)

[8.3 Common Products used in Sanitation
Procedures in Animal Shelters](#)

[8.4 Order of Cleaning and Disinfection](#)

[8.5 Where to Focus Sanitation Efforts](#)

[8.6 Sanitation of Animal Housing and Handling
Areas](#)

[8.7 Sanitation of Animal-Related Items](#)

[8.8 Sanitation for the Staff](#)

[8.9 Developing a Shelter Sanitation Plan](#)

[8.10 Conclusion](#)

[References](#)

[9 Canine and Feline Vaccinations and Immunology](#)

[9.1 Introduction](#)

[9.2 Vaccinations and Immunity](#)

[9.3 Vaccine Characteristics: Efficacy, Onset of
Action and Duration of Immunity](#)

[9.4 Vaccination Protocols for Shelters](#)

[9.5 Vaccine Handling, Administration, and Adverse
Reactions](#)

[9.6 Core Vaccines for Shelter Dogs and Cats](#)

[9.7 Optional, Non-core Vaccines for Cats and Dogs
in a Shelter](#)

[9.8 Juvenile Animals](#)

[9.9 Use of Hyperimmune Serum for Disease Prevention](#)

[9.10 Risk Assessment and Evaluation of Serologic Immunity for Canine Distemper, Canine Parvovirus and Feline Panleukopenia](#)

[9.11 Vaccine Effects on Diagnostic Testing](#)

[9.12 Conclusion](#)

[References](#)

[10 Canine Infectious Respiratory Disease \(CIRD\).](#)

[10.1 Introduction](#)

[10.2 Etiological Agents, Epidemiology, and Course of Disease](#)

[10.3 Prevalence](#)

[10.4 Diagnosis](#)

[10.5 Prevention and Control](#)

[10.6 Treatment](#)

[10.7 Implications for Foster Care and Adoption](#)

[10.8 Implications for Relocation Programs](#)

[10.9 Euthanasia Guidelines](#)

[10.10 Conclusion](#)

[References](#)

[11 Canine Distemper Virus](#)

[11.1 Introduction](#)

[11.2 Agent and Epidemiology](#)

[11.3 Transmission](#)

[11.4 Pathogenesis](#)

[11.5 Risk Factors for Infection](#)

[11.6 Incubation Period, Clinical Signs and Disease Course](#)

[11.7 Diagnosis of Canine Distemper](#)

[11.8 Treatment](#)

[11.9 Prevention, Management, and Response to Disease in the Shelter](#)

[11.10 CDV Outbreak Management](#)

[11.11 Considerations for Adoption](#)

[11.12 Conclusion](#)

[References](#)

[12 Canine Influenza](#)

[12.1 Introduction](#)

[12.2 Epidemiology of Canine Influenza Virus](#)

[12.3 Clinical Signs](#)

[12.4 Diagnosis](#)

[12.5 Treatment](#)

[12.6 Prevention and Management](#)

[12.7 Conclusion](#)

[References](#)

[13 Feline Infectious Respiratory Disease](#)

[13.1 Introduction](#)

[13.2 Causative Agents, Pathogenesis and Clinical Signs](#)

[13.3 Transmission](#)

[13.4 Clinical Epidemiology](#)

[13.5 The Effect of Environment and Shelter Type on Pathogen Prevalence](#)

[13.6 Risk Factors for Clinical Respiratory Disease](#)

[13.7 Diagnostics](#)

[13.8 Treatment](#)

[13.9 Management and Prevention of UR TD](#)

13.10 Conclusion

References

14 Canine Parvovirus and Other Canine Enteropathogens

14.1 Introduction

14.2 Canine Parvovirus-2

14.3 Other Enteropathogens

14.4 Conclusion

References

15 Feline Panleukopenia

15.1 Introduction

15.2 Epidemiology and Course of Disease

15.3 Clinical Signs

15.4 Morbidity/Mortality/Prognosis

15.5 Diagnosis

15.6 Treatment

15.7 Prevention and Control/Risk Assessment

15.8 Implications for Adoption and Foster Care

15.9 Conclusion

References

16 Feline Coronavirus and Feline Infectious Peritonitis

16.1 Introduction

16.2 Etiology

16.3 Epidemiology

16.4 Pathogenesis

16.5 Transmission

16.6 Immune Response

16.7 Clinical Signs

[16.8 Diagnosis](#)

[16.9 Treatment](#)

[16.10 Prevention and Control](#)

[16.11 Outbreak Management](#)

[16.12 Euthanasia Guidelines](#)

[16.13 Client Education/Implications for Adoption,
Relocation and Foster Care](#)

[16.14 Conclusion](#)

[References](#)

[17 Internal Parasites](#)

[17.1 Introduction](#)

[17.2 Parasite Transmission and Treatment
Considerations in Animal Shelters](#)

[17.3 Parasites with Direct Transmission](#)

[17.4 Parasites with Indirect Transmission](#)

[17.5 Conclusion](#)

[References](#)

[18 Heartworm Disease](#)

[18.1 Introduction](#)

[18.2 Lifecycle of *Dirofilaria immitis*](#)

[18.3 Transmission](#)

[18.4 Heartworm Disease in Dogs](#)

[18.5 Heartworm Disease in Cats](#)

[18.6 Heartworm Disease in Ferrets](#)

[18.7 Screening and Diagnostic Testing](#)

[18.8 Prevention](#)

[18.9 Heartworm Treatment](#)

[18.10 Conclusion](#)

[References](#)

19 External Parasites

19.1 Introduction

19.2 Ectoparasites with all Life Stages on the Host

19.3 Ectoparasites with Environmental and Host Stages

19.4 Temporary Ectoparasites Associated with Hosts Only While Feeding

19.5 Conclusion

19.A Ectoparasites Potentially Affecting Shelter Animals

References

20 Dermatophytosis

20.1 Introduction

20.2 Etiology

20.3 Pathogenesis

20.4 Disease Course

20.5 Transmission

20.6 Clinical Presentation and Differential Diagnoses

20.7 Diagnosis

20.8 Initial Risk Evaluation and Response

20.9 Treatment

20.9.1 Topical Treatment

20.10 Outbreak Management and Response

20.11 Considerations for Adoption

20.12 Conclusion

References

21 Zoonosis

21.1 Introduction

[21.2 General Guidelines for Zoonotic Disease Prevention](#)

[21.3 Zoonotic Diseases](#)

[21.4 Adoption Considerations](#)

[21.5 Consulting with the Department of Health](#)

[21.6 Conclusion](#)

[21.A Sample Animal Bite Investigation Form](#)

[References](#)

[22 Rabies](#)

[22.1 Overview of Rabies](#)

[22.2 Rabies Pathophysiology](#)

[22.3 Rabies Prevention and Control](#)

[22.4 Additional Considerations for Shelters and Shelter Animals](#)

[22.5 Conclusion and Sources of Additional Information](#)

[References](#)

[23 Feline Leukemia and Feline Immunodeficiency Viruses](#)

[23.1 Introduction](#)

[23.2 Prevention and Control](#)

[23.3 Conclusion](#)

[References](#)

[24 Exotic Companion Mammals \(Ferrets, Rabbits, Guinea Pigs and Rodents\)](#)

[24.1 Introduction](#)

[24.2 Ferrets](#)

[24.3 Rabbits](#)

[24.4 Guinea Pigs](#)

[24.5 Altricial Rodents \(Rats, Mice, Hamsters, and Gerbils\)](#)

[24.6 Conclusion](#)

[References](#)

[Index](#)

[End User License Agreement](#)

List of Tables

Chapter 2

[Table 2.1 The Five Freedoms.](#)

[Table 2.2 Recommended components of a wellness protocol for shelter cats and ...](#)

[Table 2.3 Recommended components of a wellness protocol for the shelter envir...](#)

[Table 2.4 Recommended minimum database for cats and dogs in the shelter.](#)

[Table 2.5 Resources for cat housing.](#)

Chapter 3

[Table 3.1 Annual medical profile in an adoption guarantee shelter.](#)

[Table 3.2 Log of events and protocol changes for 2015.](#)

[Table 3.3 The effect of lowering ALOS on the estimated number of cats that ca...](#)

Chapter 4

[Table 4.1 Clinical case history questions for private and shelter practice.](#)

[Table 4.2 Physical examination approach, normal findings and common abnormali...](#)

[Table 4.3 Common diagnostic tests, indications, and collection and handling t...](#)

[Table 4.4 ELISA technique variations \(Tizard 2013\).](#)

[Table 4.5 Inflammatory lesions and infectious differential diagnoses \(Rakich ...](#)

[Table 4.6 Surveillance testing sample sizes for \$\geq 90\%\$ probability of detection...](#)

Chapter 5

[Table 5.1 Reasons to perform a necropsy in a shelter.](#)

[Table 5.2 Necropsy kit.](#)

[Table 5.3 Resources for performing a complete necropsy.](#)

[Table 5.4 Necropsy and sampling for GI disease.](#)

Chapter 6

[Table 6.1 Considerations for infectious disease policies.](#)

[Table 6.2 Considerations for outbreak management plans.](#)

[Table 6.3 Considerations for disease specific protocols.](#)

[Table 6.4 Parvovirus attack rates \(AR\) for 80 shelter dogs.](#)

[Table 6.5 Parvovirus attack rate \(AR\) for 41 shelter dogs not vaccinated prio...](#)

Chapter 7

[Table 7.1 Common study types in veterinary therapeutics ranked in order of po...](#)

[Table 7.2 Questions to uncover common problems or omissions in studies releva...](#)

[Table 7.3 Selected references on compounding.](#)

[Table 7.4 Generalized spectra of antimicrobial drugs for use in selecting emp...](#)

[Table 7.5 Gram staining and oxygen requirement of major veterinary bacterial ...](#)

[Table 7.6 Pharmacodynamic parameters predicting clinical efficacy by antimicr...](#)

Chapter 8

[Table 8.1 Definitions of commonly used terms.](#)

[Table 8.2 Disinfectant products.](#)

[Table 8.3 Essential laundry basics.](#)

[Table 8.4 CDC Guidelines for proper handwashing \(CDC 2015\).](#)

[Table 8.5 The basics of hand sanitizer use.](#)

[Table 8.6 Shelter Sanitation Resources.](#)

Chapter 9

[Table 9.1 Core vaccination recommendations for animal shelters.](#)

[Table 9.2 Risk factor determination.](#)

Chapter 10

[Table 10.1 Canine infectious respiratory disease viral and bacterial agents.](#)

[Table 10.2 Prevalence data of CIRP pathogens recovered on PCR ± culture in asy...](#)

[Table 10.3 Vaccination recommendations for CIRDC in shelter-housed dogs.](#)

[Table 10.4 Anti-microbial treatment options for CIRDC in animal shelters.](#)

Chapter 12

[Table 12.1 Diagnostic test results for a canine influenza outbreak in an animal shelter.](#)

Chapter 13

[Table 13.1 Anti-viral drugs for the treatment of Feline Herpesvirus \(FHV-1\) Infection.](#)

[Table 13.2 Summary data for published clinical trials of antimicrobials in shelters.](#)

[Table 13.3 Commonly used antimicrobial treatment options for feline bacterial infections.](#)

Chapter 15

[Table 15.1 Summary of clinical signs associated with feline panleukopenia.](#)

[Table 15.2 Summary of treatment recommendations.](#)

[Table 15.3 Summary of host risk factors \(UC Davis 2016\).](#)

[Table 15.4 Summary of basic quarantine recommendations.](#)

[Table 15.5 Which vaccine to use?](#)

[Table 15.6 Sanitation recommendations.](#)

[Table 15.7 Overview of characteristics of feline panleukopenia.](#)

Chapter 16

[Table 16.1 Common nomenclature for feline coronavirus biotypes.](#)

[Table 16.2 Findings that aid in the ante-mortem diagnosis of FIP.](#)

[Table 16.3 Experimental treatments for FIP.](#)

Chapter 18

[Table 18.1 Diagnostic testing methods for microfilariae.](#)

[Table 18.2 Diagnostic test limitations.](#)

[Table 18.3 Heartworm preventives.](#)

[Table 18.4 Comparison of heartworm treatment protocols.](#)

Chapter 19

[Table 19.1 List of zoonotic vector-borne diseases that are relevant for anima...](#)

[Table 19.2 List of resources for ectoparasites and vector-borne diseases.](#)

Chapter 20

[Table 20.1 Practice tips for collecting samples and data.](#)

[Table 20.2 Sample excel sheet for recording data.](#)

[Table 20.3 Sample of an "ACTION PLAN" for culture positive animals.](#)

[Table 20.4 Organizing large numbers of culture plates.](#)

[Table 20.5 Quick guide to reading fungal culture plates.](#)

Chapter 21

[Table 21.1 List of common zoonotic pathogens \(Please review detailed informat...](#)

[Table 21.2 Common zoonotic vector-borne pathogens.](#)

[Table 21.3 Common anthroponotic pathogens.](#)

Chapter 22

[Table 22.1 Individual State Requirements Regarding Rabies Vaccine Administrat...](#)

[Table 22.2 Summary NASPHV Recommendations for Management of Rabies Exposure.](#)

Chapter 23

[Table 23.1 FeLV and FIV testing and vaccination recommendations for cats in a...](#)

Chapter 24

[Table 24.1 Classification of ferret diseases by body system.](#)

[Table 24.2 Classification of rabbit diseases by body system.](#)

[Table 24.3 Classification of Guinea pig diseases by body system.](#)

[Table 24.4 Classification of rodent diseases by body system.](#)

List of Illustrations

Chapter 2

[Figure 2.1 \(a and b\). A commercially available “cat den” serves as a secure ...](#)

[Figure 2.2 \(a and b\). Conversion of existing cages into condo-style units ca...](#)

[Figure 2.3 Outdoor section of a row of double-sided kennel runs. Indoor-outd...](#)

Chapter 3

[Figure 3.1 Incidence rate of URTD among cats by season.](#)

[Figure 3.2 Annual survival rates of un-weaned kittens in foster care 2011-20...](#)

[Figure 3.3 Average LOS of cats by age group.](#)

[Figure 3.4 Average LOS of cats with and without URTD by age group.](#)

Chapter 4

[Figure 4.1 Antibody titration.](#)

[Figure 4.2 Sensitivity, specificity and predictive value. TP, true positives...](#)

[Figure 4.3 Infectious disease diagnostic algorithm for clinical signs of com...](#)

[Figure 4.4 Infectious disease diagnostic algorithm for clinical signs of com...](#)

[Figure 4.5 Infectious disease diagnostic algorithm for clinical signs of com...](#)

Chapter 5

[Figure 5.1 The prosector takes a sample of lung. Samples taken for microbiol...](#)

[Figure 5.2 Euthanasia can cause artifactual changes to tissues. Here the gra...](#)

[Figure 5.3 Prepare to open the animal by reflecting the skin. A cut along th...](#)

[Figure 5.4 A properly opened body ready for diagnostic sampling.](#)

[Figure 5.5 Sections to be submitted for histological analysis need to be thi...](#)

[Figure 5.6 The intestines, extending from the gastroesophageal junction \(arr...](#)

[Figure 5.7 The ileo-ceco-colic junction is pictured. The intestine can be op...](#)

[Figure 5.8 Canine parvovirus \(CPV\). The intestines are segmentally thick, ed...](#)

[Figure 5.9 Feline infectious peritonitis \(FIP\) virus \(feline coronavirus\). I...](#)

Chapter 6

[Figure 6.1 Components of an infectious disease and outbreak management plan....](#)

[Figure 6.2 Point source outbreak.](#)

[Figure 6.3 Continuous source outbreak.](#)

[Figure 6.4 Propagated outbreak.](#)

[Figure 6.5 Epidemic curve stratified by location.](#)

Chapter 8

[Figure 8.1 Double compartment housing unit.](#)

[Figure 8.2 A cat with severe oral ulceration from quaternary ammonium toxic...](#)

[Figure 8.3 \(a\) Measuring the “cleanliness” of a shelter animal caregiver's sc...](#)

Chapter 11

[Figure 11.1 A young dog exhibiting squinting that can be a characteristic si...](#)

[Figure 11.2 A puppy with canine distemper exhibiting marked mucopurulent nas...](#)

Chapter 13

[Figure 13.1 \(a\) and \(b\) Ocular discharge and photophobia are common non-spec...](#)

[Figure 13.2 Housing cats near dogs should be avoided as it is stressful for ...](#)

[Figure 13.3 Prompt antimicrobial treatment is required if signs of bacterial...](#)

[Figure 13.4 Crusted discharges should be cleaned away gently using warm sali...](#)

[Figure 13.5 \(a\)-\(c\) Hiding boxes are an inexpensive and effective way to red...](#)

[Figure 13.6 Group housing in multi-cat rooms can provide enrichment for some...](#)

[Figure 13.7 Crowding and poor-quality housing poses an important risk to the...](#)

Chapter 14

[Figure 14.1 CPV outbreak response flow chart.](#)

Chapter 16

[Figure 16.1 Epidemiologic triangle representation of FIP.](#)

[Figure 16.2 Current theory of the pathogenesis of FIP.](#)

[Figure 16.3 \(a\) Ultrasound image of profound effusion in a young cat with FI...](#)

[Figure 16.4 \(a\) Effusion from a cat with FIP.\(b\) Peritoneal effusion in ...](#)

[Figure 16.5 \(a\) Feline lung with multifocal to diffuse pyogranulomas surroun...](#)

Chapter 17

[Figure 17.1 *Cystoisospora* spp. oocysts recovered through sucrose centrifugal...](#)

[Figure 17.2 Two *Toxocara canis* and numerous *Trichuris vulpis* eggs recovered ...](#)

[Figure 17.3 *Toxocara cati* egg and *Aelurostrongylus abstrusus* larva recovered...](#)

[Figure 17.4 *Toxocara cati* adult worms passed in the feces submitted for rout...](#)

[Figure 17.5 *Dipylidium caninum* egg ball recovered through a squash preparati...](#)

Chapter 18

[Figure 18.1 Heartworm lifecycle in the dog and cat.](#)

[Figure 18.2 Inflammation and thickening of the arterial parenchyma in a dog ...](#)

[Figure 18.3 A single dead adult heartworm was found at necropsy in a cat's h...](#)

[Figure 18.4 Algorithm for minimizing heartworm transmission in relocated dog...](#)

[Figure 18.5 Adult female and male heartworms. The female heartworm has a str...](#)

[Figure 18.6 The susceptibility gap.](#)

[Figure 18.7 Heartworms present in the pulmonary vasculature, and necrotic ma...](#)

[Figure 18.8 A dead worm and endarteritis in a dog treated with "slow-kill" t...](#)

Chapter 19

Figure 19.1 *Trichodectes canis*, the chewing louse of dogs. Note that the wid...

Figure 19.2 *Demodex gato* recovered on a skin scraping from an affected cat....

Figure 19.3 Large female *Sarcoptes scabiei* var. *canis* with adult male superi...

Figure 19.4 *Ctenocephalides felis* adult flea recovered from a student's apar...

Figure 19.5 Third instar calliphorid maggot recovered from an infected wound...

Chapter 20

Figure 20.1 Puppy with an area of hair loss caudal to the ear. This was caus...

Figure 20.2 Hair loss in the pre-auricular area of a cat. It was initially a...

Figure 20.3 Ear margin crusting due to dermatophytosis. This was caused by a...

Figure 20.4 Multifocal areas of hair loss on the trunk of a dog caused by a ...

Figure 20.5 Kitten with common "classical" lesions of dermatophytosis in the...

Figure 20.6 *Microsporum canis* infection on the ear of a kitten. The initial ...

Figure 20.7 "Classic" fluorescence of hairs with a Wood's lamp.

Figure 20.8 Glowing hairs on a glass slide.

Figure 20.9 The Wood's lamp can be used to locate hairs on a glass microscop...

[Figure 20.10 Note the glowing hairs on the glass slide on the microscope sta...](#)

[Figure 20.11 Glowing hairs seen through the microscope lens. In this situati...](#)

[Figure 20.12 Normal and affected hairs are present. Note that the infected h...](#)

[Figure 20.13 Cuffs of ectothrix spores seen around an infected hair \(40×\).](#)

[Figure 20.14 Box for cultures, legend embedded in the table.](#)

[Figure 20.15 Culture in the bag with a thermometer, legend embedded in the t...](#)

[Figure 20.16 Plate showing media mite growth, legend embedded in the table....](#)

[Figure 20.17 This is an actual photograph of a large number of cultures prio...](#)

[Figure 20.18 This picture demonstrates how useful the “look for the red and ...](#)

[Figure 20.19 This picture shows a fungal culture plate where the entire surf...](#)

[Figure 20.20 Microscopic examination of a suspect colony. Note the dark pigm...](#)

[Figure 20.21 Microscopic view of tape preparation of *M. gypseum*. Note the la...](#)

[Figure 20.22 \(a and b\) Microscopic examination of macroconidia of *M. canis*. ...](#)

[Figure 20.23 *M. canis distortum*. Note the distorted form of *M. canis*. This s...](#)

[Figure 20.24 Microscopic view of a young culture of *M. canis* showing common ...](#)

[Figure 20.25 Microscopic view of a Trichophyton spp. Note the large numbers ...](#)

[Figure 20.26 \(a\) Toothbrush cultures being inoculated on a plate. \(b\) Toothb...](#)

[Figure 20.27 Various commercial fungal culture mediums. Small volume and sma...](#)

[Figure 20.28 \(a-c\) This series of pictures is representative of a P1, P2, an...](#)

[Figure 20.29 In this facility, red tape is used on the floor to designate a ...](#)

[Figure 20.30 In order to control environmental contamination, a conscious ef...](#)

[Figure 20.31 This is a portable treatment station. It is comprised of a plas...](#)

[Figure 20.32 Portable rose garden sprayer used to apply topical treatment so...](#)

[Figure 20.33 Application of lime sulfur to a cat using a garden sprayer. Not...](#)

[Figure 20.34 Commercial Swiffer clothes are excellent ways to mechanically r...](#)

[Figure 20.35 "Swiffer kit" for environmental sampling.](#)

[Figure 20.36 The Swiffer should be wiped over the target area until visibly ...](#)

Chapter 22

[Figure 22.1 Cases of animal rabies in the United States 1957-2007.](#)

[Figure 22.2 Cases of rabies among wildlife in the United States, by year and...](#)

[Figure 22.3 Distribution of major rabies virus variants in mesocarnivores in...](#)

[Figure 22.4 \(a-f\) Reported cases of rabies in several species of wild and do...](#)

[Figure 22.5 Map of vaccination laws by state in the United States and Puerto...](#)

[Figure 22.6 Template algorithms for handling animals and humans exposed to r...](#)

Chapter 23

[Figure 23.1 The most common mode of FIV transmission is from bite wounds. A ...](#)

[Figure 23.2 Following FeLV infection, a strong immune response suppresses vi...](#)

[Figure 23.3 Sample FeLV and FIV screening protocol beginning with point-of-c...](#)

Chapter 24

[Figure 24.1 \(a\) Ferret cage.\(b\) Caging used for dogs and cats can be ada...](#)

[Figure 24.2 Most ferrets can be handled for examination or treatment by hold...](#)

[Figure 24.3 Restraint of a rabbit with one hand under its thorax and the oth...](#)

[Figure 24.4 Restraint of a stressed rabbit by covering its eyes and supporti...](#)

[Figure 24.5 To help facilitate examination or medication administration a to...](#)

[Figure 24.6 Restraint of a guinea pig by fully supporting their weight with ...](#)

Infectious Disease Management in Animal Shelters

Second Edition

Edited by

Lila Miller, BS, DVM

Vice President, Shelter Medicine (retired)

*American Society for the Prevention of Cruelty to Animals
(ASPCA)*

New York, NY, USA

***Stephanie Janeczko, DVM, MS, DABVP (Shelter
Medicine and Canine/Feline Practice), CAWA***

Vice President, Shelter Medicine Services

Director, Julie Morris Shelter Medicine Residency Program

American Society for the Prevention of Cruelty to Animals

New York, NY, USA

***Kate F. Hurley, DVM, MPVM, DABVP (Shelter
Medicine Practice)***

Director, UC Davis Koret Shelter Medicine Program

Assistant Clinical Professor

Shelter Medicine and Small Animal Population Health

School of Veterinary Medicine

University of California

Davis, CA, USA

WILEY Blackwell

This edition first published 2021
© 2021 John Wiley & Sons, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Lila Miller, Stephanie Janeczko, Kate F. Hurley to be identified as the authors of the editorial material in this work has been asserted in accordance with law.

Registered Office

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

Editorial Office

111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or

disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data

Names: Miller, Lila, editor. | Janeczko, Stephanie, editor. | Hurley, Kate, editor.
Title: Infectious disease management in animal shelters / edited by Lila Miller, Stephanie Janeczko, Kate F. Hurley.

Description: Second edition. | Hoboken, NJ : Wiley-Blackwell, 2021. | Includes bibliographical references and index.

Identifiers: LCCN 2021007215 (print) | LCCN 2021007216 (ebook) | ISBN 9781119294351 (paperback) | ISBN 9781119294375 (adobe pdf) | ISBN 9781119294368 (epub)

Subjects: MESH: Communicable Diseases-veterinary | Communicable Disease Control | Animal Diseases-prevention & control | Animal Welfare

Classification: LCC SF781 (print) | LCC SF781 (ebook) | NLM SF 781 | DDC 636.089/69-dc23

LC record available at <https://lccn.loc.gov/2021007215>

LC ebook record available at <https://lccn.loc.gov/2021007216>

Cover Design: Wiley

Cover Image: © (clockwise from left): Courtesy of Stephanie Janeczko; Courtesy of Sandra Newbury; Courtesy of Bridget Chariton; Courtesy of Jennifer Graham

This textbook is dedicated to the memory of Julie Morris, an animal welfare visionary who was one of the first to recognize the importance of integrating veterinary medicine directly into animal sheltering to improve and save the lives of homeless animals. Her early support of shelter veterinarians and shelter medicine training and programs was responsible for many of the advancements in the field, including this textbook. She is missed tremendously as a mentor, colleague, friend, and leader by the editors of this text and by many others.